ImmunityBio推进一线BCG初治NMIBC项目 患者入组超预期且Anktiva®联合BCG中期分析结果积极

美股速递
Jan 16

ImmunityBio公司宣布,其针对一线BCG初治非肌层浸润性膀胱癌的研发项目取得显著进展。目前患者入组人数已超出预期目标,同时Anktiva®与BCG联合疗法的中期分析显示出积极结果。这一里程碑为后续临床开发奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10